Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
Teva Pharmaceutical Industries Limited reports developments across its global pharmaceutical business, including complex generic medicines, biosimilars, pharmacy brands, and innovative medicines in neuroscience and immunology. News commonly covers financial results, investor conference presentations, R&D updates, regulatory milestones, and product or patient-support launches tied to brands and candidates such as UZEDY, PONLIMSI, and proposed biosimilars.
As an Israel-based issuer with ADSs traded under TEVA, company updates also address ADR-relevant investor communications, operating outlook materials, partnerships, and strategy around a generics platform supporting a broader biopharmaceutical portfolio.
Teva (NYSE:TEVA) reported Q1 2026 revenue of $3,982 million, up 2% in U.S. dollars and down 3% in local currency. Key innovative brands grew strongly (AUSTEDO $578M, AJOVY $196M, UZEDY $63M) while generics declined; PONLIMSI received FDA approval and Teva agreed to acquire Emalex, expected to close by Q3 2026.
GAAP diluted EPS $0.31; non-GAAP diluted EPS $0.53; free cash flow $188 million; 2026 outlook maintained and updated for Emalex.
Teva (NYSE:TEVA) will acquire Emalex Biosciences for $700 million upfront, plus up to $200 million in commercial milestones and royalties on global net sales of ecopipam, subject to regulatory approval. Ecopipam is an NDA-ready, first-in-class selective D1 antagonist for pediatric Tourette syndrome with FDA Orphan Drug and Fast Track designations and positive Phase 3 primary endpoint results; NDA submission is anticipated in 2H 2026. The deal is expected to close by Q3 2026, funded from Teva cash on hand, and Teva said it will seek to mitigate near-term margin dilution while remaining on track for its 2027 targets.
Teva (NYSE: TEVA) launched Home Ground™ Schizophrenia Community on April 15, 2026, an online, no‑cost platform offering peer‑informed resources, symptom‑tracking tools, emotional‑wellness content, independent‑living guides, physical‑health prompts and event listings to support people living with schizophrenia and their care partners.
Content was developed with input from people living with schizophrenia, care partners and advocacy groups to reduce isolation and augment clinical care.
Teva (NYSE:TEVA), Direct Relief, and the National Association of Free and Charitable Clinics announced a second round of grants of $75,000 each to 11 free and charitable clinics in Alabama, Mississippi, and Texas on April 14, 2026. Teva previously committed an additional $2 million in 2024 after a 2022 launch.
In 2025 the grantee programs reached more than 57,000 people, completed nearly 6,000 depression and anxiety screenings, and trained over 260 providers. Funding supports expanded counseling, extended hours, telehealth, and outreach.
Teva (NYSE:TEVA) announced FDA approval of PONLIMSI (denosumab-adet) for all Prolia indications and acceptance of BLA/MAA filings for a proposed omalizumab biosimilar in the U.S. and EU. The EMA granted marketing authorization for PONLIMSI in November 2025, and FDA approval occurred on March 30, 2026.
Teva positions these regulatory milestones as part of its Pivot to Growth strategy to expand its global biosimilars portfolio and commercialization capabilities.
Teva (NYSE: TEVA) posted its Q1 2026 Aide Memoire to the Investors page to help investors ahead of first-quarter results. The document compiles previously disclosed public information, management commentary and select independent data.
Teva expects to release Q1 2026 results on April 29, 2026 at 7:00 AM ET, with a conference call at 8:00 AM ET.
Teva (NYSE: TEVA) will release its first quarter 2026 financial results on April 29, 2026 at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET the same day. Registration is required for phone participation and a replay will be available within 24 hours on Teva's investor website.
Teva (NYSE: TEVA) and Blackstone Life Sciences announced a $400 million strategic funding agreement over four years to support development of duvakitug, a human monoclonal antibody targeting TL1A in phase 3 studies for ulcerative colitis and Crohn’s disease.
BXLS may earn regulatory and commercial milestones plus low single-digit royalties on worldwide sales, and Teva remains co-developer/co-commercializer with Sanofi subject to regulatory approval.
Teva (NYSE: TEVA) announced that President and CEO Richard Francis will participate in three investor conferences in March 2026: UBS European Healthcare Conference (Mar 3, investor meetings only), Leerink Partners Global Healthcare Conference (Mar 9, 10:00 AM ET, webcast fireside chat), and Barclays 28th Annual Global Healthcare Conference (Mar 10, 8:00 AM ET, webcast fireside chat).
Live webcasts and archived recordings (available within 24 hours, accessible for up to 30 days) will be hosted on Teva's Investor Relations website.
Teva (NYSE: TEVA) announced FDA acceptance of its New Drug Application for TEV-'749, an investigational once-monthly subcutaneous olanzapine extended-release injectable suspension on Feb 20, 2026.
The NDA is supported by Phase 3 SOLARIS Week 56 results showing efficacy and safety consistent with existing olanzapine formulations and no evidence requiring post-injection monitoring; TEV-'749 uses Medincell's SteadyTeq sustained-release copolymer technology.